Janus Henderson Investors — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)in
BoardHelen S. Kim(Director)Oleg Nodelman(Director)inAndrew Levin(Director)
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundRA CapitalTCG Crossover+4 more
Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology imaging and treatment of advanced solid tumors, along with ALXN1840, a late-stage investigational treatment for Wilson Disease, a rare genetic disorder.
BiotechHealthtechMedical DevicesLake Forest, US
Chandler D. Robinson(Executive Officer, Director, Promoter)inChristopher M. Starr(Executive Officer, Director)Andrew P. Mazar(Executive Officer, Director)
BoardMichael J. Brown(Director)
Co-investorsRA Capital
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)in
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.